Original article. E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P.
|
|
- Madison Miles
- 5 years ago
- Views:
Transcription
1 Original article Annals of Oncology 15: , 2004 DOI: /annonc/mdh267 Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P. Rougier 1 1 CHU Ambroise Pare, AP-HP, Boulogne-Billancourt; 2 Centre Rene Gauducheau, Saint-Herblain, France; 3 University Hospital Gasthuisberg, Leuven, Belgium; 4 Royal Marsden Hospital, London, UK; 5 Aventis, Paris, France Received 8 January 2004; revised 25 February 2004; accepted 27 February 2004 Introduction Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinotecan also improves survival in second-line treatment. Patients and methods: Univariate and multivariate analyses based on the individual data of 602 patients included in two phase III trials were performed to determine predictive factors of survival in advanced colorectal cancer. Results: Three factors were independently associated with a better progression-free survival: weight loss < 5% [hazard ratio (HR) 1.25; 95% confidence interval (CI) ], World Health Organization performance status (WHO PS) 0 1 (HR 1.29; 95% CI ) and irinotecan (CPT-11)-containing regimens (HR 1.48; 95% CI ). Five factors were independently associated with a better overall survival: weight loss < 5% (HR 1.67; 95% CI ), WHO PS 0 1 (HR 1.88; 95% CI ), one or two metastatic sites (HR 1.24; 95% CI ), alkaline phosphatase values not over twice the normal range (HR 1.71; 95% CI ) and CPT-11-containing regimens (HR 1.31; 95% CI ). Conclusions: The present analysis confirms that CPT-11-based chemotherapy regimens are independently associated with a better survival in patients with advanced colorectal cancer. Age was not identified as a prognostic factor in this analysis. Key words: chemotherapy, colorectal neoplasms, irinotecan, prognostic factors Initially used alone, and then in combination with folinic acid (FA), 5-fluorouracil (5-FU) has been the main chemotherapy drug for the treatment of advanced colorectal cancer (ACC) for the past 40 years. A meta-analysis including 1219 patients demonstrated that continuous 5-FU infusion is superior to bolus administration in terms of response rate and survival, with less toxicity [1]. In Europe, the most widely used continuous infusion regimens of 5-FU are the LV5FU2 regimen [2], the AIO (Arbeitsgemeinschaft Internische Onkologie, German Cooperative Group for Oncology) regimen [3, 4] and the Spanish Cooperative Group For Gastrointestinal Tumor Therapy *Correspondence to: Dr E. Mitry, Service d hépato-gastroentérologie et oncologie digestive, CHU Ambroise Paré, AP-HP, 9 avenue Charles de Gaulle, Boulogne, France. Tel: ; Fax: ; emmanuel.mitry@apr.ap-hop-paris.fr TTD regimen [5]. Compared with the Mayo Clinic regimen, the LV5FU2 regimen is less toxic and significantly increases tumor response rate and progression-free survival (PFS), with a modest increase in overall survival (OS) [2]. The AIO regimen also increased PFS compared with the Mayo Clinic regimen in one randomized trial [3, 6], whereas in another trial the TTD regimen did not significantly improved PFS and OS compared with the Mayo Clinic regimen [5]. Irinotecan (CPT-11) is used in combination with these regimens. Two randomized trials have demonstrated that the infusional 5-FU (LV5FU2 and AIO regimens) in combination with CPT-11 significantly increase PFS [7, 8], while a significant advantage in terms of OS has been demonstrated in one trial [7], compared with the same regimens without CPT-11 in front-line treatment of ACC. CPT- 11 also improves survival in second-line treatment compared with best supportive care [9] or infusional 5-FU [10]. Studies evaluating prognostic factors of survival in ACC patients treated with a bolus 5-FU-based regimen [11] or with q 2004 European Society for Medical Oncology
2 1014 the irinotecan (CPT-11)-based IFL (CPT-11 5-FU leucovorin) regimen [12] have recently been published, but there were no available data on prognostic factors of survival in patients treated with the LV5FU2 or AIO regimen, with or without CPT-11. We have therefore performed a pooled analysis of data from the two published randomized trials using infusional based 5-FU regimens with or without CPT-11 [7, 10]. Patients and methods Analyses were based on individual data of 602 patients treated in the V302 [10] and V303 [7] trials. The methodology and results of these trials have been published previously. Trial V302 [10] Trial V302 included 267 patients (256 treated) whose cancer had progressed after 5-FU-based treatment and who where randomized to either CPT-11 monotherapy or infusional 5-FU (AIO, LV5FU2 or Lockich regimens). Patient entry criteria included: age years; histologically proven progressive metastatic adenocarcinoma of the colon or rectum; World Health Organization performance status (WHO PS) of <_ 2; and adequate hematological, renal and hepatic functions. One hundred and twentyseven patients were randomly allocated to CPT mg/m 2 as a 90-min intravenous infusion once every 3 weeks (300 mg/m 2 in patients aged > 70 years or with WHO PS 2). One hundred and twenty-nine patients were randomly assigned to 5-FU by continuous infusion and received the LV5FU2, AIO or Lockich regimen. The LV5FU2 regimen consisted of FA 200 mg/m 2 intravenously over 2 h followed by 5-FU 400 mg/m 2 intravenous bolus followed by 5-FU 600 mg/m 2 continuous intravenous infusion over 22 h/day on the first 2 days of every 2-week period. The AIO regimen consisted of 5-FU g/m 2 /day intravenously over 24 h with or without FA mg/m 2 /day intravenously weekly for 6 weeks, with 2-week rests between cycles. Thirty-nine patients treated with the Lockich regimen were not included in the present analysis, since this regimen was not used in the V303 trial. Trial V303 [7] Trial V303 included a total of 387 patients (385 treated) with ACC who were randomized to first-line treatment with infusional 5-FU (AIO or LV5FU2) with or without CPT-11. Patients had to meet the following criteria: age years; histologically proven adenocarcinoma of the colon or rectum; WHO PS of <_ 2; adequate hematological, renal and hepatic functions; and no previous chemotherapy other than adjuvant chemotherapy finished > 6 months before randomization. For the no CPT-11 group (186 patients), the AIO and LV5FU2 regimens were the same as for the V302 trial. For the CPT-11 group (199 patients), the regimens were: once weekly CPT mg/m 2 with fluorouracil 2300 mg/m 2 in a 24 h infusion, plus FA 500 mg/m 2 (AIO-CPT-11 regimen); or every 2 weeks, CPT mg/m 2 on day 1 with 5-FU 400 mg/m 2 bolus and 600 mg/m 2 by 22 h infusion, plus FA 200 mg/m 2 on days 1 and 2 (LV5FU2-CPT-11 regimen). Statistical analysis PFS was calculated from the date of randomization to the date of progression (or date of death in patient without progression). OS was calculated from the date of randomization to the date of death. The survival function was estimated using the Kaplan Meier method [13]. The first part of the analysis consisted of the univariate comparison of survival functions for factors that could potentially affect the survival time using the log rank test. Univariate analysis describes the survival with respect to the factor under investigation, but necessarily ignores the impact of any others. We therefore performed a multivariate survival analysis to compare prognostic factors of survival after adjustment for the impact of other factors [14]. Different potential predictive variables were evaluated in univariate analyses: age (< 65 versus years), sex, weight loss (< 5% versus >_ 5%), WHO PS (0 1 versus 2), tumor site (colon versus rectum), number of metastatic sites (1 2 versus >_ 3), liver metastases (yes versus no), lung metastases (yes versus no), peritoneal carcinomatosis (yes versus no), serum carcinoembryonic antigen (CEA) value (<_ 50 versus > 50 ng/ml), alkaline phosphatase value [<_ 2 N upper normal limit() versus > 2N], lactate dehydrogenase (LDH) value (N versus > N), leukocyte count (< versus >_ /mm 3 ), treatment line (1 versus 2) and CPT-11-containing regimen (yes versus no). A Cox proportional hazard regression, stratified on treatment line, was performed to estimate prognostic factors associated with survival in the multivariate analysis. The LDH value was only available for 503 patients and was excluded from the multivariate analysis. All other variables associated with survival in the univariate analysis at the 0.1 level were entered into the Cox model. The calculations were performed using Stata statistical software (Stata Corporation, College Station, TX, USA). Results Patients Six hundred and two patients were included in the analysis: 217 treated in V302 trial and 385 treated in V303 trial. There were 358 males and 244 females, with a median age of 50 years (range 24 75). Patient characteristics at the time of randomization are presented in Table 1. Table 1. Patient characteristics at time of randomization and survival by trial and treatment Trial V303 n Males Age group, years < Weight loss < 5% WHO PS organs involved PFS in months (95% CI) OS in months (95% CI) Irinotecan group ( ) 17.4 ( ) No irinotecan group ( ) 14.1 ( ) Trial V302 Irinotecan group ( ) 10.8 ( ) No irinotecan group ( ) 7.9 ( ) WHO PS, World Health Organization performance status; PFS, progression-free survival; CI, confidence interval; OS, overall survival.
3 1015 Predictive factors of PFS Variables significantly associated with PFS in the univariate analysis were: weight loss, PS, number of metastatic sites, alkaline phosphatase, LDH, treatment line and CPT-11-containing regimens (Table 2). The comparisons for age and liver metastases only just reached the 0.05 significance level. Whereas patients with CEA > 50 ng/ml had the same median PFS as those with a lower CEA value, the log rank test was highly significant (P = 0.01) because the survival curve diverged after the fifth month. Results of the multivariate analysis are presented in Table 3. Three factors were independently associated with a better PFS: weight loss < 5% [hazard ratio (HR) 1.25; 95% confidence interval (CI) ; P = 0.047], WHO PS 0 1 (HR 1.29; 95% CI ; P = 0.005) and CPT-11 containing regimens (HR 1.48; 95% CI ; P = 0.035). Age was not associated with PFS. Predictive factors of OS Variables significantly associated with OS in the univariate analysis were: weight loss, PS, number of metastatic sites, peritoneal carcinomatosis, CEA value, alkaline phosphatase value, LDH value, treatment line and an CPT-11-containing regimen (Table 2). Results of the multivariate analysis are presented Table 4. Five factors were independently associated with a better OS in multivariate analysis: weight loss < 5% (HR 1.67; 95% CI ; P< 0.001), WHO PS 0 1 (HR 1.88; 95% CI ; P = 0.002), two or less metastatic sites (HR 1.24; 95% CI ; P = 0.04), alkaline phosphatase <_2 N (HR 1.71; 95% CI ; P< 0.001) and CPT-11-containing regimen (HR 1.31; 95% CI ; P = 0.009). Age was not associated with OS. Discussion This pooled analysis based on the individual data of 602 patients treated either with CPT-11 monotherapy or an infusional 5-FU-based regimen with or without CPT-11 in two randomized trials confirms the prognostic role of previously identified factors such as PS and weight loss and add to the existing data on patients treated with CPT-11. Khöne et al. [11] recently published a multivariate analysis of 3825 patients with 5-FU-based treatment for metastatic colorectal cancer. PS, number of metastatic sites, white blood cell count and alkaline phosphatase were the main clinical parameters associated with survival, and were correlated with three risk groups for patients: low, medium and high, with corresponding median survivals of 15, 10.7 and 6.1 months. The major prognostic significance of PS has previously been reported in several studies [9, 12, 15 17] and indeed, a good performance status (WHO 0 1) is associated with a better PFS or OS in our analysis. As also reported previously [9], weight loss > 5% was independently associated with a worse PFS and OS. The number of metastatic sites, CEA, alkaline Table 2. Factors associated with progression-free survival (PFS) and overall survival (OS) in the univariate analysis n Median PFS (months) P Median OS (months) Sex Male Female Age, years < Weight loss < 5% Yes < No WHO PS < Tumor site Colon Rectum No. metastatic sites Liver metastases No Yes Lung metastases No Yes Peritoneal carcinomatosis No Yes CEA, ng/ml <_ < > Alkaline phosphatase 2 N < >2 N White blood cells (/mm 3 ) < >_ LDH N < < > N Treatment lines < Irinotecan-containing regimen Yes No WHO PS, World Health Organization performance status; CEA, carcinoembryonic antigen; LDH, lactate dehydrogenase. P
4 1016 Table 3. Factors associated with a better progression-free survival in multivariate analysis (Cox proportional hazard regression stratified on treatment line) Hazard ratio 95% CI P value WHO PS Weight loss < 5% Irinotecan-containing regimen CI, confidence interval; WHO PS, World Health Organization performance status. Table 4. Factors associated with a better overall survival in multivariate analysis (Cox proportional hazard regression stratified on treatment line) Hazard ratio 95% CI P value WHO PS Weight loss < 5% < <_ 2 metastatic sites Alkaline phosphatase <_ 2 N < Irinotecan-containing regimen CI, confidence interval; WHO PS, World Health Organization performance status. phosphatase and LDH were significantly associated with PFS and OS in the univariate analysis. In the multivariate analysis, no tumor-related factors were associated with PFS, whereas the number of metastatic sites and alkaline phosphatase were significantly associated with OS, as previously reported [9, 11, 12, 18]. Despite a strong association with survival in the univariate analysis, LDH was not introduced in the multivariate analysis, since its value was not available for almost 20% of the patients and this may have distorted the regression results. A CPT-11-based regimen also independently predict for a better PFS and OS compared with 5-FU-based regimen, which was previously demonstrated in randomized trials [7, 8, 10, 19]. A CPT-11-based regimen seems to be the most important factor associated with PFS (HR 1.48 compared with 1.29 for PS and 1.25 for weight loss), but PS and weight loss remain the main prognostic factors for OS (HR 1.88 and 1.71, respectively, compared with 1.31 for CPT-11). Age was not associated with survival, and patients between 65 and 75 years old had the same prognosis as younger patients. It was noted that multivariate analyses results were similar when 70 years was chosen as the cut-point for young and elderly patients. Age has rarely been reported as a prognostic factor of colorectal cancer survival in randomized trials [20], whereas epidemiological data clearly show that patients above the age of 75 years have a worse prognosis than younger patients [21, 22], mainly because they are less frequently actively treated. By design, most clinical trials in colorectal cancer have limited recruitment to generally fit patients < 75 years old, and very few data on efficacy and tolerance of the current standard regimen are available for this population. This is problematic, since the incidence of colorectal cancer in the elderly is steadily increasing, with > 40% of the cases occurring in patients aged 75 years and above [23]. A subgroup analysis performed among patients treated with the LV5FU2 CPT-11 regimen in the V303 trial demonstrated that there was no difference in tumoral response rate or PFS and OS rates for patients aged between 65 and 75 or younger patients [24], but more data in patients older than 75 years is needed to confirm treatment recommendations. To resolve this issue, randomized clinical trials focusing on elderly patients are awaited, and indeed, the Fédération Francophone de Cancérologie Digestive is conducting a study comparing treatment by LV5FU2 or simplified LV5FU2 with the same regimen with CPT-11 (LV5FU2-CPT-11 and FOLFIRI regimens) in the first-line treatment of ACC in patients aged 75 years and above. Trials such as this one will enable us to confirm whether the prognostic factors identified in this analysis for patients under 75 years old hold true for those over 75. References 1. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: Weh HJ, Wilke HJ, Dierlamm J et al. Weekly therapy with folinic acid (FA) and high-dose fluorouracil (5-FU) 24 h infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1994; 5: Köhne CH, Wils J, Lorenz M et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study J Clin Oncol 2003; 21: Aranda E, Diaz-Rubio E, Cervantes A et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998; 9: Schmoll H, Khöne C, Lorenz M et al. Weekly 24 h Infusion of highdose (HD) 5-fluorouracil (5-FU24 h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): a randomized phase III study of the EORTC GITCCG and the AIO. Proc Am Soc Clin Oncol 2000; 20: 241a (Abstr 935). 7. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial (published erratum appears in Lancet 2000; 355: 1372). Lancet 2000; 355: Köhne C, Van Custem E, Wils J et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI group study Proc Am Soc Clin Oncol 2003; 22: 254 (Abstr 1018). 9. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:
5 Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: Köhne CH, Cunningham D, Di CF et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: Knight R, Miller L, Pirotta N et al. First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators. Proc Am Soc Clin Oncol 2000; 19: 255a (Abstr 991). 13. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer 2003; 89: Assersohn L, Norman A, Cunningham D et al. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 1999; 79: Kouri M, Pyrhonen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992; 49: Steinberg J, Erlichman C, Gadalla T et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 1992; 28A: Chang AE, Steinberg SM, Culnane M, White DE. Determinants of survival in patients with unresectable colorectal liver metastases. J Surg Oncol 1989; 40: Saltz L, Douillard JY, Pirotta N et al. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2000; 19: 242a (Abstr 938). 20. Kosmidis PA, Tsavaris N, Skarlos D et al. Fluorouracil and leucovorin with or without interferon a-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. J Clin Oncol 1996; 14: Mitry E, Bouvier AM, Estève J, Faivre J. How to explain the improvement in survival for colorectal cancer? A French populationbased study. Eur J Cancer 2003; 1: S326 (Abstr). 22. Martijn H, Voogd AC, van de Poll-Franse LV et al. Improved survival of patients with rectal cancer since 1980: a population-based study. Eur J Cancer 2003; 39: Remontet L, Esteve J, Bouvier AM et al. Cancer incidence and mortality in France over the period Rev Epidemiol Sante Publique 2003; 51: Rougier P, Mitry E, Cunningham D et al. Is age a prognostic factor of toxicity and efficacy in patients (pts) with metastatic colorectal cancer (MCRC) receiving irinotecan in combination with 5FU/folinic acid (FA). Proc Am Soc Clin Oncol 2003; 22: 267 (Abstr 1072).
Update on Chemotherapy for Advanced Colorectal Cancer
Review Article [1] March 02, 2001 By Daniel G. Haller, MD [2] Efforts to improve the length and quality of life, as well as to expand treatment options, for patients with metastatic colorectal cancer have
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationIrinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination
Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationIntegrating Oxaliplatin into the Management of Colorectal Cancer
Integrating Oxaliplatin into the Management of Colorectal Cancer HANS-JOACHIM SCHMOLL, a JIM CASSIDY b a Martin-Luther-University Halle-Wittenberg, Halle, Germany; b University of Aberdeen, Aberdeen, UK
More informationEfficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
Original article Annals of Oncology 15: 1330 1338, 2004 doi:10.1093/annonc/mdh344 Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W
癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationOWa 22 80) :IEZ
Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More information療指引 34 Adjuvant Therapy of Colon Cancer
療指引 34 Adjuvant Therapy of Colon Cancer mfolfox6 Oxaliplatin 85 1 Q2W 1~3, 10 FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin 500 1,8,15,22,29,35 Q8W 5-FU 500 1,8,15,22,29,35 Q8W Capecitabine Capecitabine
More informationOriginal article. Introduction
Original article Annals of Oncology 14: 1106 1114, 2003 DOI: 10.1093/annonc/mdg288 A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic
More informationORIGINAL ARTICLE. M. Bakogeorgos, G. Mountzios, G. Kotsantis, P. Economopoulou, N. Fytrakis, N. Kentepozidis. Summary.
JBUON 2013; 18(3): 629-634 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationONCOLOGY LETTERS 2: , 2011
ONCOLOGY LETTERS 2: 241-245, 2011 Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following
More informationTreatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations
Treatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations D Papamichael MB BS FRCP On behalf of the SIOG CRC in the Elderly Task Force Madrid 10/11/07 8 th Meeting of the International
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationReview. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials
Review Annals of Oncology 15: 545 549, 2004 DOI: 10.1093/annonc/mdh127 Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical
More informationKey words: advanced colorectal cancer, metastatic, irinotecan, 5-fluorouracil, leucovorin.
Original Article 297 Decreasing Dosage of Irinotecan, 5-Flurouracil (5-FU) and Leucovorin (LV) in the Treatment of Advanced and /or Metastatic Colorectal Cancer: A Phase II Study Jen-Seng Huang, MD; Cho-Li
More informationUnresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationCytotoxic Chemotherapy for Advanced Colorectal Cancer
Review Article [1] November 02, 2005 By Scott Kopetz, MD [2] and Paulo M. Hoff, MD, FACP [3] Several developments in the past few years have incrementally progressed the field and provided additional insights
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationOriginal article. Introduction
Original article Annals of Oncology 13: 716 720, 2002 DOI: 10.1093/annonc/mdf091 Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the
More informationclinical practice guidelines
Annals of Oncology 21 (Supplement 5): v93 v97, 2010 doi:10.1093/annonc/mdq222 Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment E. Van Cutsem 1, B. Nordlinger 2 & A. Cervantes
More informationFOLFOX in Patients Aged Between 76 and 80 Years With Metastatic Colorectal Cancer
2666 FOLFOX in Patients Aged Between 76 and 80 Years With Metastatic Colorectal Cancer An Exploratory Cohort of the OPTIMOX1 Study Arie Figer, MD 1 Nathalie Perez-Staub, MD 2 Elisabeth Carola, MD 3 Christophe
More informationUnderstanding predictive and prognostic markers
Understanding predictive and prognostic markers Professor Aimery de Gramont Chairman of ARCAD Foundation and GERCOR, Paris FRANCE Understanding predictive and prognostic markers Aimery de Gramont Prognostic
More informationtrial update clinical
clinical trial update by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UMPC Cancer Centers In order to provide the most up-to-date and efficacious care to their patients, oncologists must
More informationOriginal article. 5-Fluorouracil versus 5-fluorouracil plus a-interferon as treatment of metastatic colorectal carcinoma. A randomized study*
Annals of Oncology 7: 575-579, 1996. O 1996 Kluwer Academic Publishers. Printed in the Netherlands. Original article 5-Fluorouracil versus 5-fluorouracil plus a-interferon as treatment of metastatic colorectal
More informationCetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience
JBUON 2016; 21(1): 70-79 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Cetuximab in third-line therapy of patients with metastatic colorectal
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationTherapy for Metastatic Colorectal Cancer
Therapy for Metastatic Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Learning Objectives Key
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationType Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily
Colorectal - Adjuvant Standard adjuvant therapy for Duke's C Day(s) Drug Dose Route Comments and high risk Duke's B Colorectal cancer 5-FU/FA Weekly 1 Folinic acid 50mg IV IV Bolus injection via fast running
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationCLINICAL INVESTIGATION
Research Article CLINICAL INVESTIGATION Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI: Efficacy and toxicity of first-line treatment in stage IV metastatic colorectal
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More information大腸直腸癌 抗癌藥物治療指引 討論日期 團隊討論 : 105 年 10 月 19 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 1 月 25 日 核備日期 : 106 年 4 月 18 日
大腸直腸癌 抗癌藥物治療指 討論日期 團隊討論 : 05 年 0 月 9 日 三院討論 : 05 年 2 月 7 日 團隊確認 : 06 年 月 25 日 核備日期 : 06 年 4 月 8 日 Adjuvant Therapy of Colon Cancer mfolfox6 參考文獻 -3 Oxaliplatin 85 Q2W 2 Leucovorin 400 Q2W 2 5-FU 400 Q2W
More informationColorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors
Symposium article Annals of Oncology 14 (Supplement 2): ii25 ii29, 2003 DOI: 10.1093/annonc/mdg725 Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors
More informationAnalysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials
Gastric Cancer (2017) 20:481 488 DOI 10.1007/s10120-016-0629-x ORIGINAL ARTICLE Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored
More informationComparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From
Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03,
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationOpinion 17 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 October 2012 VECTIBIX 20 mg/ml, concentrate for solution for infusion B/1 vial of 5 ml (CIP code: 3400957181857)
More informationOriginal article. P. Rougier 1 *, D. Lepille 2, J. Bennouna 3, A. Marre 4, M. Ducreux 5, L. Mignot 6, A. Hua 7 & D. Méry-Mignard 7.
Original article Annals of Oncology 13: 1558 1567, 2002 DOI: 10.1093/annonc/mdf259 Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal
More informationCase Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases
Case Reports in Oncological Medicine, Article ID 790192, 4 pages http://dx.doi.org/10.1155/2014/790192 Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Muhammad
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 18 JUNE 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Weekly Infusional High-Dose Fluorouracil (), Plus Folinic Acid (/FA), or /FA Plus Biweekly Cisplatin in Advanced
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More informationThe International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice
Editorial The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationAdjuvant therapy in older adults: controversies and challenges - Colorectal cancer -
International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie
More informationAdjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma
JBUON 2014; 19(4): 906-912 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Adjuvant chemotherapy outcomes in patients over 65 years with early
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationA retrospective analysis of the safety and efficacy of apatinib in treating advanced metastatic colorectal cancer
Oncology and Translational Medicine DOI 10.1007/s10330-017-0235-5 October 2017, Vol. 3, No. 5, P210 P216 ORIGINAL ARTICLE A retrospective analysis of the safety and efficacy of apatinib in treating advanced
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationChemotherapy re-challenge response rate in metastatic colorectal cancer
Original Article Chemotherapy re-challenge response rate in metastatic colorectal cancer Alexandra E. Chambers 1, Jacob Frick 1, Natalee Tanner 1, Richard Gerkin 2, Madappa Kundranda 3, Tomislav Dragovich
More informationCHEMOTHERAPY FOR METASTATIC GASTRIC CANCER
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain
More informationAdjuvant therapy in colon cancer: which treatment in 2005?
Annals of Oncology 16 (Supplement 4): iv69 iv73, 2005 doi:10.1093/annonc/mdi911 Adjuvant therapy in colon cancer: which treatment in 2005? F. Di Costanzo* & L. Doni Medical Oncology Unit, Department of
More informationANTICANCER RESEARCH 26: (2006)
Clinical Impact of Adjuvant Chemotherapy on Patients with Stage III Colorectal Cancer: l-lv/5fu Chemotherapy as a Modified RPMI Regimen is an Independent Prognostic Factor for Survival TSUKASA HOTTA, KATSUNARI
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationWeekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection
Original article Annals of Oncology 15: 568 573, 2004 DOI: 10.1093/annonc/mdh134 Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after
More informationKonzepte bei der Therapie des metastasierten kolorektalen Karzinoms
21. Ärzte Fortbildungskurs in Klinischer Onkologie 24.-26. Februar 2011 Kantonspital St. Gallen / Schweiz Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms Claus-Henning Köhne Klinik
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationUpdated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)
Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationBevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
226 research article Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience Janja Ocvirk 1,2, Maja Ebert Moltara 1,Tanja Mesti
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationChemotherapy options and outcomes in older adult patients with colorectal cancer
Critical Reviews in Oncology/Hematology 72 (2009) 155 169 Chemotherapy options and outcomes in older adult patients with colorectal cancer Muhammad W. Saif a,, Stuart M. Lichtman b a Yale University School
More informationHyponatremia in small cell lung cancer is associated with a poorer prognosis
Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationFOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell Italia Meridionale (GOIM)
Annals of Oncology 16 (Supplement 4): iv56 iv60, 2005 doi:10.1093/annonc/mdi909 FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell Italia Meridionale (GOIM) E.
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationEfficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma
1931 Efficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma A 10-Year Experience of the Geisinger Medical Center Farid Fata, M.D. 1 Ayoub Mirza, M.D. 2 G. Craig Wood, M.S.
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationNICE Health Technology Re-appraisal. Submission of the British Association of Surgical Oncology- The Association for Cancer Surgery
NICE Health Technology Re-appraisal The use of irinotecan, oxaliplatin and raltitrexed in the treatment of advanced colorectal cancer (review of guidance No. 33) Submission of the British Association of
More informationTobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1
Botrel et al. BMC Cancer (2016) 16:677 DOI 10.1186/s12885-016-2734-y RESEARCH ARTICLE Open Access Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated
More informationComparison of first-line bevacizumab in combination with mfolfox6 or XELOX in metastatic colorectal cancer
JBUON 2015; 20(2): 460-467 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Comparison of first-line bevacizumab in combination with mfolfox6 or
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationThe role of Maintenance treatment Appropriate endpoints according to ESMO consensus
ESMO Preceptorship Programme Colorectal Cancer Singapore-October 20-22 2016 JY Douillard, MD, PhD, CMO ESMO The role of Maintenance treatment Appropriate endpoints according to ESMO consensus MAINTENANCE
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationRESEARCH ARTICLE. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
RESEARCH ARTICLE Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis Yusuke Sasaki 1,2, Tetsuya Hamaguchi 1 *, Yasuhide Yamada
More informationCurative treatment strategies for colorectal
EVALUATING DRUGS FOR COLORECTAL CANCER: RECENT CLINICAL TRIALS Robert J. Ignoffo, PharmD ABSTRACT Until the late 1990s, fluorouracil (FU) plus leucovorin (LV) was the standard adjuvant therapy for stage
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationRECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER
RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS
More information